Molecure S.A.

Warsaw Stock Exchange MOC.WA

Molecure S.A. Price to Sales Ratio (P/S) on January 14, 2025: 1,481,732.57

Molecure S.A. Price to Sales Ratio (P/S) is 1,481,732.57 on January 14, 2025, a -52.28% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Molecure S.A. 52-week high Price to Sales Ratio (P/S) is 3,333,719.89 on February 12, 2024, which is 124.99% above the current Price to Sales Ratio (P/S).
Molecure S.A. 52-week low Price to Sales Ratio (P/S) is 1,445,005.75 on November 18, 2024, which is -2.48% below the current Price to Sales Ratio (P/S).
Molecure S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 2,393,382.14.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Warsaw Stock Exchange: MOC.WA

Molecure S.A.

CEO	Dr. Marcin Jan Szumowski Ph.D.
IPO Date	April 1, 2018
Location	Poland
Headquarters	Zwirki i Wigury 101
Employees	105
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.

Key trends

Past 5 years